Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion type Assertion NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_head.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion description "[Because these tumours tend to be less sensitive than other types of GTD to chemotherapy, the most successful regimen to date has been with EMA/CO or EMA/EP.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_provenance.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion evidence source_evidence_literature NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_provenance.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion SIO_000772 14614893 NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_provenance.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion wasDerivedFrom befree-20150227 NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_provenance.
- NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_assertion wasGeneratedBy ECO_0000203 NP385999.RAw9RDwHB9ROU0i6Fc3xusmZi0K85-oPtL5UVp4cPWBI8130_provenance.